

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

UD-SCC-2

RRID:CVCL_E325

Type: Cell Line

Proper Citation

RRID:CVCL_E325

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_E325

Proper Citation: RRID:CVCL_E325

Description: Cell line UD-SCC-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hypopharyngeal squamous cell carcinoma

Defining Citation: [PMID:10628319](#), [PMID:15495191](#), [PMID:16331601](#), [PMID:18487078](#), [PMID:20215515](#), [PMID:24201445](#), [PMID:25275298](#), [PMID:28236344](#), [PMID:29156801](#), [PMID:30894373](#), [PMID:31541927](#)

Comments: Virology: Contains from 14 to 23 copies of the HPV16 genome (PubMed=24201445)., Population: Caucasian., Part of: OPC-22 oral and pharyngeal cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: UD-SCC-2

Synonyms: UD-SCC 2, UD-SCC2, UDSCC-2, UDSCC2, University of Dusseldorf-Squamous Cell Carcinoma-2

Cross References: cancercellines:CVCL_E325, Cell_Model_Passport:SIDM00025, Cosmic:932282, Cosmic:2296311, Cosmic-CLP:1299073, DepMap:ACH-002391, GDSC:1299073, GEO:GSM3631261, Pharmacodb:UDSCC2_1638_2019, Progenetix:CVCL_E325, Wikidata:Q54990107

ID: CVCL_E325

Record Creation Time: 20220427T221650+0000

Record Last Update: 20260913T010311+0000

Ratings and Alerts

No rating or validation information has been found for UD-SCC-2.

No alerts have been found for UD-SCC-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wu H, et al. (2026) USP4-mediated deubiquitination of NOTCH1 inhibits HNSCC progression through regulating oxidative stress and ferroptosis. International immunopharmacology, 186, 117071.

Korns J, et al. (2026) Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(2), 405.

Fehn A, et al. (2025) 5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells. Neoplasia (New York, N.Y.), 59, 101086.

Yadollahi P, et al. (2025) Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. British journal of cancer, 133(12), 1802.

Sen P, et al. (2025) CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma. Frontiers in immunology, 16, 1528520.

Abou Kors T, et al. (2024) INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression. Cancer research communications, 4(2), 571.

Sannigrahi MK, et al. (2022) HPV E6 regulates therapy responses in oropharyngeal cancer by repressing the PGC-1 β /ERR α axis. JCI insight, 7(18).

Hoppe-Seyler K, et al. (2021) Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells. *International journal of cancer*, 149(5), 1137.

Wilkat M, et al. (2020) Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells. *International journal of cancer*, 147(1), 202.

Sakai A, et al. (2020) Aberrant expression of CPSF1 promotes head and neck squamous cell carcinoma via regulating alternative splicing. *PloS one*, 15(5), e0233380.

Carper MB, et al. (2019) An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma. *Cell reports*, 29(6), 1660.

Jin L, et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. *Cancer cell*, 34(2), 315.